Health Controversies Again #249

January 24, 2014

This week, we're looking at controversial topics at the intersection of healthcare and ethics. Law professor and author Timothy Caulfield returns to discuss the rise of stem cell tourism at clinics worldwide. And science writer David Dobbs joins us to explain the showdown between the U.S. Food and Drug Administration and personal genomics company 23andMe.

Guests:

  • Timothy Caulfield
  • David Dobbs

Guest Bios

Timothy Caulfield

Timothy Caulfield is a Canada Research Chair in Health Law and Policy and a Professor in the Faculty of Law and the School of Public Health at the University of Alberta. He is also the Research Director of the Health Law and Science Policy Group (HeaLS). Over the past several years, he has been involved in a variety of interdisciplinary research endeavours that have allowed him to publish over 250 articles and book chapters. He has won numerous academic awards, publishes frequently in the popular press, has been involved with a number of national and international policy and research ethics committees and is the author of the bestselling book "The Cure for Everything: Untangling the Twisted Messages about Health, Fitness and Happiness". He is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

David Dobbs

David Dobbs writes books as well as features and essays for The New York Times, National Geographic, The Atlantic, Pacific Standard, Slate, Aeon, Nature, and other publications. His magazine features are regularly chosen for leading anthologies, and he is now writing his fourth book, "The Orchid and the Dandelion" due out in 2015. When Dobbs isn’t working, he likes to hike, bike, fish, bird, garden, ski, paddle, or play with his camera.